What is Lifesci Capital's Estimate for SLNO Q4 Earnings?

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Lifesci Capital issued their Q4 2024 earnings estimates for shares of Soleno Therapeutics in a research report issued to clients and investors on Tuesday, February 4th. Lifesci Capital analyst M. Belghiti forecasts that the company will earn ($0.37) per share for the quarter. Lifesci Capital has a "Strong-Buy" rating on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics' Q1 2025 earnings at ($1.67) EPS, Q2 2025 earnings at ($1.13) EPS, Q3 2025 earnings at ($1.03) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.32) EPS, Q1 2026 earnings at ($1.55) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($1.54) EPS, FY2027 earnings at $5.58 EPS, FY2028 earnings at $9.47 EPS and FY2029 earnings at $9.99 EPS.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($1.22).

SLNO has been the topic of several other reports. Oppenheimer boosted their price target on Soleno Therapeutics from $65.00 to $73.00 and gave the company an "outperform" rating in a research note on Monday, October 28th. Stifel Nicolaus reissued a "buy" rating and set a $74.00 target price on shares of Soleno Therapeutics in a research note on Monday, December 2nd. Robert W. Baird reaffirmed an "outperform" rating and issued a $72.00 price target on shares of Soleno Therapeutics in a research note on Monday, December 2nd. Finally, HC Wainwright reissued a "buy" rating and set a $70.00 price objective on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Soleno Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $71.20.

Soleno Therapeutics Stock Performance

Shares of NASDAQ:SLNO traded down $0.61 during midday trading on Thursday, reaching $50.37. The company's stock had a trading volume of 337,128 shares, compared to its average volume of 425,934. Soleno Therapeutics has a fifty-two week low of $36.61 and a fifty-two week high of $60.92. The firm has a 50 day moving average price of $47.18 and a two-hundred day moving average price of $49.87. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -15.17 and a beta of -1.46.

Hedge Funds Weigh In On Soleno Therapeutics

A number of hedge funds have recently bought and sold shares of SLNO. AlphaQuest LLC lifted its position in shares of Soleno Therapeutics by 1,154.4% during the fourth quarter. AlphaQuest LLC now owns 715 shares of the company's stock valued at $32,000 after purchasing an additional 658 shares in the last quarter. E Fund Management Co. Ltd. purchased a new position in shares of Soleno Therapeutics in the 4th quarter worth approximately $211,000. Arizona State Retirement System grew its holdings in shares of Soleno Therapeutics by 27.4% in the fourth quarter. Arizona State Retirement System now owns 6,760 shares of the company's stock valued at $304,000 after acquiring an additional 1,454 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Soleno Therapeutics by 13.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 217,550 shares of the company's stock valued at $9,779,000 after acquiring an additional 24,953 shares during the last quarter. Finally, US Bancorp DE bought a new stake in Soleno Therapeutics during the fourth quarter worth $34,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Soleno Therapeutics

In related news, insider Kristen Yen sold 2,340 shares of Soleno Therapeutics stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $46.18, for a total transaction of $108,061.20. Following the transaction, the insider now owns 76,605 shares of the company's stock, valued at $3,537,618.90. The trade was a 2.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bhatnagar Anish sold 10,937 shares of the company's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total value of $496,649.17. Following the sale, the chief executive officer now owns 708,616 shares of the company's stock, valued at $32,178,252.56. This trade represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 17,360 shares of company stock valued at $790,119 over the last three months. Corporate insiders own 12.30% of the company's stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.